WASHINGTON, D.C. (July 28, 2021) — Today Joanne Duncan is joining the Association for Accessible Medicines as Chief Operating Officer. She will be responsible for leading and managing implementation of a more comprehensive member recruitment strategy. She will drive operational improvement by increasing the alignment between issue prioritization and the budgeting process, maximizing IT functionality and human resources capabilities.
With her breadth and depth of experience, Joanne is certain to play a pivotal role taking AAM to the next level advocating for patient access to generic and biosimilar medicines in these exciting and challenging times,
said AAM CEO Dan Leonard. We are thrilled to welcome Joanne to AAM.
Before joining AAM, Joanne served as President, Membership and Business Operations Division at the Biotechnology Innovation Organization (BIO). In this role, she oversaw the revenue-generating components at the $86 million revenue association including membership, meetings, finance and operations. Prior to her time at BIO, Joanne served as SVP and CFO of the Credit Union National Association (CUNA) and Senior Vice President, Strategic Business Development at America’s Health Insurance Plans (AHIP).
Joanne earned her bachelor’s degree from Randolph-Macon College and a master’s in taxation from George Mason University. She is a Certified Public Accountant (CPA) and a Certified Association Executive (CAE).
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.